PRPF18

Across TCGA pan-cancer cohorts, PRPF18 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PRPF18 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher PRPF18 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRPF18 expression acts as an unfavorable survival marker.

ESCA, BLCA, and COAD are the cancer types where PRPF18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.102	0.703	<.001	24	view →
BLCA	DFS	Median	III,IV	0.116	0.575	<.001	14	view →
COAD	OS	Median	III,IV	0.168	0.692	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PRPF18–ESCA (OS)

Open the ESCA breakdown →